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78 Poster Session IObjective:Cord blood stem cells are routinely used in transplant
for hematological malignancies. Many nonmalignant disorders,
particularly genetic disorders, require allogeneic transplantation,
but autologous transplantation is also possible. This report docu-
ments 17 cord blood units (CBU) released by one bank for treat-
ment of nonmalignant hematopoietic disorders. Methods: Cord
blood was collected from the umbilical cord of consenting mothers
who elected to store CBU, however, directed donation was offered
to families with an individual diagnosed with a disease treatable with
stem cells. The whole blood product was processed at the Cord
Blood Registry laboratory in Tucson, AZ to separate mononuclear
cells (MNC) from red blood cells and non-engrafting cells. The
processed CBU were cryopreserved until requested for use. Prior
to release, viability and HLA were assessed.Results:Of 56 CBU re-
leased for transplant, 17 (30.4%) were for nonmalignant disorders: 3
thalassemia, 2 Fanconi anemia, 1 Hurler syndrome, 2 sickle cell ane-
mia, 6 aplastic anemia, 1 x-linked hyper IGM syndrome, 1 Diamond
Blackfan anemia, and 1 Wolman disease. 13 (76.5%) of 17 were
from a sibling, but 4 aplastic anemia transplants were autologous.
The 17 samples were stored a mean of 28.38 months (range: 2–
114), mean patient age was 5.4 years, and mean period of engraft-
ment was 18.94 days (range: 2–36), with a mean of 0.77%
CD341 cells. All units were viable for transplant. The patient
with Wolman disease died 17 days post-transplant due to unrelated
complications, engraftment was not evaluable. Conclusion: Cord
blood stem cells are increasingly common for patients with nonma-
lignant blood and marrow disorders, and the availability of sibling
cord blood decreases risk of transplant-related morbidity and mor-
tality. Nonmalignant disorders represent a third of all transplants
facilitated by this family bank, suggesting that they are a significant
indication for cord blood transplantation. Directed donation or pri-
vate banking should be considered for siblings of patients with
a nonmalignant disorder treatable with stem cells.





500 (days) StatusBeta Thalassemia Sibling 3.3 5 17 CuredFanconi Anemia Sibling 5.0 12 24 CuredHurler Syndrome Sibling 2.6 2 12 Deceased -
organ failure;
cardiomyopathySickle Cell Anemia Sibling 9.8 29 23 CuredAplastic Anemia Auto 2.7 32 36 Deceased -
infection;
aspergillusSickle Cell Anemia Sibling 2.4 2 35 CuredBeta Thalassemia Sibling 7.1 5 13 CuredX-linked Hyper
IGM SyndromeSibling 3.1 7 14 UnknownFanconi Anemia Sibling 11.5 27 13 Deceased -
hemorrhage
post-liver biopsyAplastic Anemia Auto 3.0 36 2 RemissionAplastic Anemia Sibling 2.9 6 27 RemissionBeta Thalassemia Sibling 0.3 44 16 CuredAplastic Anemia Auto 4.9 58 29 RelapsedAplastic Anemia Auto 9.6 114 21 RemissionAplastic Anemia Sibling 5.3 24 7 RemissionDiamond Blackfan
AnemiaSibling 10.1 24 14 CuredWolman Disease Sibling 0.2 27 Unevaluable Deceased -
respiratory
failure210
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
FOR HEMATOLOGIC MALIGNANCIES AFTER REDUCED INTENSITY CON-
DITIONING (RIC) IN CHILDREN AND YOUNG ADULTS
Duerst, R.E., Jacobsohn, D.A., Tse, W., Schneiderman, J., Kletzel, M.
Children’s Memorial Hospital, Feinberg School of Medicine, Northwest-
ern University, Chicago, IL.RIC regimens and allogeneic HSCT are used to treat adults with
malignancies, relying on cellular graft-vs-malignancy effects. Age or
co-morbid conditions do not preclude treatment. RIC regimens
could potentially reduce long-term morbidity, enhancing the qual-
ity of life in pediatric survivors of HSCT.
We report the experience of 44 RIC HSCT for children/young
adult patients (pts) with hematologic malignancies, 33 at high-risk
for complications of full-intensity conditioning due to disease state,
prior HSCT (5 allo, 7 auto) and/or co-morbidities. The RIC regi-
men was comprised of fludarabine, 150 mg/m2 over 5 days, followed
by IV busulfan, 0.8–1 mg/kg for 8 doses (n 5 14) or targeted AUC
4000 microMol*min for 2 doses (n5 30) and ATG. 10 pts received
extracorporeal photopheresis (ECP), and not ATG.
Diagnoses included: ALL (18,$CR3 in 9), AML (9, refractory in
3), CML (6), Non-Hodgkin’s Lymphoma (5), Hodgkin’s Lym-
phoma (2) or treatment-related myelodysplastic syndrome (4).
There were 26 males, 18 females, ages 2–21 yrs, median 11. Stem
cell sources included 22 unrelated donors (URD), 20 matched
sibs and 2 mis-matched relatives. 42 of 44 stem cell donations
were mobilized peripheral blood. Graft-versus-host disease
(GVHD) prophylaxis was cyclosporin A (CsA) alone in 11 pts,
CsA and mycophenolate (MMF) in 24 pts or CsA with MMF and
post-HSCT ECP in 9 patients.
The median time to reach an ANC.500/mcl was 19 days (range
9–62). An unsupported Plt Ct. 20,000/mcl was achieved in 40 pts
at a median of 17 days (7–228), 14 pts required no platelet support. 2
pts with URD failed to engraft and 2 had graft loss. 8 pts developed
Gr III-IV acute GVHD, 11 of the 34 pts surviving more than 100
days developed chronic GVHD (5 limited, 6 extensive). Sustained
full (.95%) donor chimerism was achieved in 24 pts.
13 pts survive without disease relapse or progression. 22 pts re-
lapsed or had molecular evidence of persistent disease. Of these, 3
pts are alive in subsequent remission following immune modula-
tion, 5 are in remission after further therapy (4 HSCT) and 5 con-
tinue therapy. 9 pts died after disease recurrence. Another 9 pts have
died, 7 from opportunistic infections, 2 from hyperacute GVHD.
Thus, the projected 3-year survival in this very high-risk group of
pts is 44%.
Our results suggest a graft vs malignancy effect can be harnessed
and RIC allogeneic HSCT should be considered for pediatric pts,
especially those at high-risk for complications after conventional
HSCT.211
HAPLOIDENTICAL STEM CELL TRANSPLANTATION USING T- AND B-
LYMPHOCYTE DEPLETED GRAFTS FOLLOWING REDUCED INTENSITY
CONDITIONING FOR WISKOTT-ALDRICH SYNDROME
Kasow, K.A., Madden, R., Barfield, R., Leung, W., Hale, G.A. St. Jude
Children’s Research Hospital, Memphis, TN.
Wiskott - Aldrich syndrome (WAS) is a rare X-linked syndrome
characterized by micro- thrombocytopenia, eczema, and immuno-
deficiency, curable only through allogeneic hematopoietic stem
cell transplantation (HSCT). A mismatched family member is an
option when no matched related or unrelated donor is available.
Our team recently treated two young males, ages 1 year and 4 years,
who were enrolled on a prospective clinical trial using haploidenti-
cal HSCT for WAS. One donor was a 3/6 HLA-matched mother
and the other a 4/6-HLA matched father. A reduced intensity con-
ditioning (RIC) regimen consisting of fludarabine, thiotepa, mel-
phalan and OKT3 was administered. To reduce the risk of severe
graft-versus-host disease (GVHD) and EBV-lymphoma (PTLPD),
patients received a G-CSF mobilized peripheral blood stem cell
product depleted of T- and B-lymphocytes using the CliniMACS.
To facilitate engraftment, 1–2.5  105 CD31 cells/kg were added
to the graft. Cyclosporine was initiated on day -2 and continued un-
til day1100, then tapered in the absence of GVHD. The length of
hospitalization was 26 and 44 days. They received grafts containing
between 7.9–25.95  106 CD341 cells/kg and received 1.6–3.3 
104 CD191 cells/kg. Both demonstrated myeloid engraftment on
days 10 and 11 and achieved platelet engraftment of 50,000/mm3
by days 13 and 15. Only one patient, the one who received the lower
T-cell dose, experienced GHVD; he had grade 1 acute GHVD,
